top of page
Leading the Way in Intratumoral Radiotherapeutics
News
Categories
Sign up
Featured Posts
Archive
Follow Us
Alpha Tau to Participate at Jefferies Global Healthcare Conference in London
JERUSALEM, November 11, 2025 -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT ® , today announced that CFO Raphi Levy will participate at the Jefferies Global Healthcare Conference in London on November 18-19, 2025. Event: Jefferies Global Healthcare Conference Format: 1X1 Investor meetings Date: November 18-19, 2025 Location: London Mr. Levy will be available for 1x1 i
Nov 11, 2025
Alpha Tau Announces Receipt of Radioactive Material License for its New Hampshire Manufacturing Facility, Advancing Towards Commercial Readiness
- Receipt of critical license marks significant milestone for first commercial-scale manufacturing facility for Alpha DaRT®, the innovative alpha-radiation cancer therapy designed for potent and conformal tumor irradiation - - License paves way for introduction of radioactive material and continued positive momentum toward initiating Alpha DaRT treatment manufacturing in 2026 - Jerusalem, October 21, 2025 - Alpha Tau Medical Ltd . (Nasdaq: DRTS, DRTSW) ("Alpha Tau"), the deve
Oct 21, 2025
Alpha Tau Successfully Treats First Patient in its U.S. Multi-Center Pancreatic Cancer Clinical Trial
- First patient treatment marks successful initiation of multi-center pilot study in Alpha DaRT U.S. pancreatic cancer program – - Study...
Sep 2, 2025
Alpha Tau to Participate in Five September Investor Conferences
JERUSALEM, August 27, 2025 -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the...
Aug 27, 2025
Alpha Tau to Present at Jefferies Global Healthcare Conference
JERUSALEM, May 28, 2025 -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative...
May 28, 2025
Alpha Tau Announces First Quarter 2025 Financial Results and Provides Corporate Update
- Interim Jan-2025 results from three trials of Alpha DaRT® in treating pancreatic cancer shared at prestigious 2025 ASCO GI Symposium...
May 20, 2025
Alpha Tau Announces Appointment of Nadav Kidron to its Board of Directors
JERUSALEM, May 12, 2025 -- Alpha Tau Medical Ltd. (Nasdaq: DRTS , DRTSW ), ("Alpha Tau" or the "Company"), the developer of the...
May 13, 2025
Alpha Tau to Participate in May Investor Conferences
JERUSALEM, May 6, 2025 -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative...
May 6, 2025
Alpha Tau Announces Closing of $36.9 Million Registered Direct Offering and Strategic Marketing Alliance with Oramed Pharmaceuticals
- Investment comes at a pivotal moment for Alpha Tau, which is experiencing remarkable growth on multiple fronts, with four active U.S....
Apr 28, 2025
Alpha Tau Receives FDA Approval to Initiate a Trial for Patients with Recurrent Glioblastoma
JERUSALEM, April 2, 2025 – Alpha Tau Medical Ltd. (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy...
Apr 2, 2025
bottom of page